ALTSTATION.IO

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

By Nova Skye | AltStation.io | Updated November 06, 2026

Price

$905.73

Change

+0.31%

Market Cap

$93.70B

Avg Volume

775.9K

Company Overview

Regeneron Pharmaceuticals is a commercial-stage biotechnology company founded in 1988 and headquartered in Tarrytown, New York. They develop and manufacture prescription medicines targeting major eye disorders, severe inflammatory conditions, cancer, and cardiovascular diseases. Their primary commercial lineup includes Dupixent for asthma and eczema, EYLEA injections for macular degeneration and diabetic eye conditions, Libtayo for skin cancer, Kevzara for rheumatoid arthritis, and Praluent for severe cholesterol disorders. These treatments are distributed worldwide to healthcare systems, specialty clinics, and retail pharmacies.

Regeneron operates as an established market leader in ophthalmology and immunology, driven by the massive adoption of EYLEA and Dupixent. Their competitive edge comes from proven antibody discovery capabilities and global commercial alliances, including a key partnership with Bayer to commercialize EYLEA and EYLEA 8 mg. The biggest threat to their position is revenue concentration in legacy blockbusters, making them vulnerable to competing therapies in the crowded retinal disease and oncology spaces. To defend their territory, they focus on upgrading standard treatments with higher-dose formulations while scaling proven immunology indications.

Right now, the company is pivoting toward next-generation therapeutic modalities through aggressive pipeline dealmaking. Regeneron has locked down strategic collaborations in CRISPR and gene editing with Intellia and Tessera, RNAi therapeutics with Alnylam, and radiopharmaceuticals and bispecifics with Telix and CytomX. They have also entered the high-demand metabolic category by licensing HS-20094, a dual GLP-1/GIP receptor candidate from Hansoh Pharmaceuticals. This external development push is crucial for establishing their next wave of clinical growth.

Key Financials

Market Cap

$93.70B

Revenue

$16.90B

EBITDA

$5.65B

Gross Margin

46.7%

Profit Margin

28.5%

Revenue Growth

36.3%

Total Cash

$9.30B

Total Debt

$2.71B

Free Cash Flow

$2.58B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

20.02

Forward P/E

12.81

Beta

0.10

52-Week High

$991.73

52-Week Low

$591.52

EPS

$45.24

50-Day Avg

$802.45

200-Day Avg

$741.59

Price/Book

2.71

Technical Analysis

REGN trades at $905.73, placing it 78% of the way from its $590.83 52-week low to its $991.73 high. The stock is 8.96% below that high and 52.82% above the low. Price sits 8.79% above the 20-day moving average of $829.95, backed by gains of 10.28% over five trading days and 22.08% over 20 trading days. Near-term support is $726.47, while the 30-day high of $973.36 is the immediate resistance level. The trend is strong, but REGN is approaching the upper end of its recent range.

Recent News and Developments

Regeneron crushes third-quarter estimates

Third-quarter revenue rose 36% year over year to $5.116 billion, while non-GAAP earnings climbed 70% to $20.07 per share. EYLEA HD U.S. sales increased 62% to $699 million, and Libtayo global sales rose 51% to $550 million. Source: GlobeNewswire

REGN surges after earnings beat

REGN jumped 8.1% in premarket trading on October 30, reaching $885 after adjusted earnings beat the $16.06 consensus by $4.01 per share. Revenue of $5.12 billion also cleared the $4.54 billion estimate. Source: Investing.com

BofA raises REGN target to $1,030

BofA Securities raised its REGN price target from $908 to $1,030 while maintaining its Buy rating. The firm said third-quarter revenue came in 12% above its expectations, driven by Dupixent, EYLEA and Libtayo. Source: StreetInsider

Market Sentiment and Analyst Recommendations

Bull Case

Revenue growth of 36.3% is the clearest reason to own REGN. Third-quarter revenue rose 36% to $5.116 billion, while non-GAAP earnings increased 70% to $20.07 per share. EYLEA HD U.S. sales climbed 62% to $699 million, and Libtayo global sales grew 51% to $550 million. The company also has $9.30 billion in cash against $2.71 billion in debt, giving it substantial financial flexibility. At $905.73, the stock remains below the $977.93 analyst target and BofA’s newly raised $1,030 target. Cemdisiran’s expected FDA decision this month provides another near-term catalyst. With a 20.02 P/E and accelerating product sales, the growth supports the valuation.

Bear Case

REGN is already 52.82% above its 52-week low and sits 78% of the way through its 52-week range. That leaves less room for disappointment after a 22.08% gain over the last 20 trading days. Price is also 8.79% above its 20-day moving average, so momentum has become stretched relative to the recent trend. The $977.93 consensus target is above the current $905.73 price, but the low analyst target of $812 is below it. Near-term resistance at $973.36 and the 52-week high at $991.73 could limit further gains without another strong catalyst. The pending cemdisiran FDA decision creates binary regulatory risk because the outcome could materially affect sentiment. REGN’s $2.71 billion in debt is manageable against $9.30 billion in cash, but it still belongs in the risk calculation.

What to Watch

The first item is the FDA’s expected decision this month on cemdisiran for generalized myasthenia gravis. Investors should also watch whether EYLEA HD can maintain momentum after U.S. sales rose 62% to $699 million. Libtayo is another key growth test following a 51% increase in global sales to $550 million. The next earnings update needs to show that third-quarter revenue of $5.116 billion and non-GAAP earnings of $20.07 per share were not one-off peaks. On the chart, a move above $973.36 would clear near-term resistance and put the $991.73 52-week high in play. A drop below the $829.95 20-day moving average would weaken the current momentum signal, while $726.47 remains the stated near-term support. The thesis improves if product growth remains strong and cemdisiran wins approval; it weakens if sales slow or the stock loses those technical levels.

Analyst Consensus

BUY

Based on 27 analyst opinions

Low Target

$812.00

Mean Target

$977.93

High Target

$1175.00

Earnings and Financial Data

Sector

Healthcare

Industry

Biotechnology

Employees

15,410

Earnings & Dividends

Next Earnings

Jan 28, 2027

EPS (Trailing)

$45.24

Dividend Yield

42.0%

Payout Ratio

8.2%

Frequently Asked Questions

Is REGN a good stock to buy?

The consensus recommendation is buy based on 27 analysts, and REGN has reported revenue growth of 36.3%. The clear takeaway is that analysts are bullish, but the stock is already 78% of the way through its 52-week range.

What is REGN’s price target?

The analyst target is $977.93, with estimates ranging from $812 to $1,175. The takeaway is that expectations vary widely around the current $905.73 price.

What is REGN’s 52-week high and low?

The technical price series shows a 52-week high of $991.73 and a low of $590.83. The takeaway is that REGN trades 8.96% below its high and 52.82% above its low.

Is REGN overvalued?

REGN trades at a P/E of 20.02 with reported revenue growth of 36.3%. The takeaway is that the valuation must be judged against strong growth, but the provided data does not establish that the stock is overvalued.

What are REGN’s support and resistance levels?

Near-term support is the 30-day low of $726.47, while resistance is the 30-day high of $973.36. The takeaway is that those are the key technical levels to track around the current $905.73 price.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated November 06, 2026.